

Partner, Washington, D.C.

Antitrust/Competition



T: 202.371.7146
julia.york@skadden.com

Education

J.D., Columbia University School of Law, 2001 (Harlan Fiske Stone Scholar)

B.A., Amherst College, 1997 (German Studies)

Bar Admissions

District of Columbia
Illinois

Languages

German

Julia York has represented numerous global corporations in various industries, including pharmaceuticals, telecommunications, energy and financial markets, in both litigation and transactional matters.

Selected experience includes:

- defending Sprint Corp. in a lawsuit brought by state attorneys general challenging the proposed acquisition of Sprint by T-Mobile;
- defending Actavis, Inc. in a suit brought by the Federal Trade Commission (FTC), including before the U.S. Supreme Court, challenging the legality of a patent litigation settlement;
- defending Actavis, Inc. and a Teva Pharmaceuticals U.S., Inc. affiliate in multidistrict “reverse-payment” class action litigation related to the brand-name drug AndroGel 1%;
- defending Medicis Pharmaceutical Corp. in multidistrict “reverse-payment” class action litigation related to the acne product Solodyn;
- representing Johnson-Matthey in a suit brought by Actelion Pharmaceuticals Ltd. against multiple prospective generic manufacturers involving monopolization and restraint of trade claims in connection with Actelion’s REMS and restricted pharmaceutical distribution programs;
- representing brand-name and generic pharmaceutical companies in connection with FTC investigations and inquiries;
- defending a pharmaceutical company CEO in a challenge to an FTC investigation;
- defending Nokia in an antitrust challenge to its IP licensing practices by Apple;
- defending Energy Transfer Partners in an antitrust class action alleging conspiracy and predatory pricing in the Texas natural gas market; and
- representing a financial futures exchange during a U.S. Department of Justice (DOJ) investigation into a proposed joint venture.

Ms. York also counsels clients on various antitrust matters and has participated on panels discussing antitrust issues relevant to the pharmaceutical industry. Ms. York actively works on *pro bono* matters, including representing various *amici curiae* on briefs submitted to the U.S. Supreme Court and various U.S. Circuit Courts of Appeal. She has been recognized in *The Legal 500 U.S.* and *Lawdragon 500*.

Prior to joining Skadden, Ms. York counseled clients from diverse industries in connection with DOJ and FTC investigations into mergers and acquisitions. Other prior experience included representing a television industry client in a DOJ criminal price-fixing investigation, as well as representing a telecommunications industry client and an aluminum industry client in international arbitration proceedings in Switzerland.

Selected Publications

“Recent Antitrust Developments Underscore Administration’s Focus on Labor Markets,” *Skadden, Arps, Slate, Meagher & Flom LLP*, February 8, 2022

“FTC Chair Khan Highlights Key Policy Priorities Going Forward, but Aggressive Agenda Faces Uphill Climb,” *Skadden, Arps, Slate, Meagher & Flom LLP*, October 4, 2021